SREBF1 and metabolic disease: Thus, the activation of PPARα, LXR, and SREBP-1c, and their regulation of SCD1 are potential pathways in metabolic diseases, but the mechanisms of action in some tissues (e.g., the kidneys) have not yet been elucidated.